From Big Pharma to Biotech CEO
About this episode
This episode features Rachel Sha, CEO of Terrestrial Bio, discussing her journey from Big Pharma to leading a biotech company.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rachel Sha, CEO at Terrestrial Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with Rachel, covering: Navigating the Genzyme Sanofi acquisition and building a leadership career on the other side of the transaction Being in the right place at the right time to pursue entrepreneurship, and the steep learning curve of stepping into a biotech CEO role The decision to adopt a dual strategy, partnering with biopharma on a platform technology while also advancing internal programs Leading a $50M Series C raise in a challenging funding environment and evolving the company’s identity The real world trade offs between building manufacturing capabilities in house versus outsourcing to CDMOs Rachel Sha is the CEO at Terrestrial, a company focused on transforming the delivery of next generation therapies with its microarray skin patch that provides a patient friendly experience that is injection free and without the hassle of cold chain. Prior to Terrestrial, she was an Operating Partner at Engine Ventures, a venture fund spun-out of…
More episodes of Molecule to Market: Inside the outsourcing space
Explore listener stats, chart rankings, contacts and more on the Molecule to Market: Inside the outsourcing space podcast page.